STAT Plus: Court invalidates Biogen’s patent on blockbuster multiple sclerosis drug
RUBY WALLAU FOR STAT
The ruling gives Mylan the right to launch its own version of Tecfidera within days, although Biogen said it planned to appeal.
Suscribirse a:
Enviar comentarios (Atom)
.png)
No hay comentarios:
Publicar un comentario